ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1286

Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis

Bret Sohn1, Erin Wilfong 1 and Leslie Crofford 1, 1Vanderbilt University, Nashville

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: dermatomyositis and systemic sclerosis, interstitial lung disease, Myositis, synthetase syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Muscle Biology, Myositis & Myopathies Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The purpose of this study is to compare the prevalence, physiology, and radiographic findings in IIM as well as to analyze the utilization of screening/monitoring plans in different clinical and antibody defined patient subsets. 

Methods: Patients diagnosed with polymyositis (PM), dermatomyositis (DM), anti-aminoacyl tRNA synthetase syndrome (ARS), limited cutaneous systemic sclerosis (lcSS), or diffuse cutaneous systemic sclerosis (dcSS) were identified from the MYSTIC cohort (VUMC IRB 141415) and using subject locator (VUMC IRB 180672). The presence of ILD was identified from chart abstraction. Radiographic patterns of ILD were ascertained from the initial CT scan. American Thoracic Society (ATS) criteria were used to grade severity of lung disease by forced vital capacity (FVC) and diffusion lung capacity for carbon monoxide (DLCO) percentages. If multiple pulmonary function tests (PFTs) were available, the most severe value was used. Symptom onset was defined as the start of any clinical manifestation of IIM or SSc. 

Results: Patient characteristics are shown in Table 1. Sixty-nine of 131 patients had ILD with the highest prevalence in ARS (81.5%) and dcSS (71.4%). Overall, most patients had CT morphology other than usual interstitial pneumonia (UIP) (Table 2). Non-Jo1 (45.5%) ARS were most frequently classified as UIP. Severe restriction was present in 36.4% of Jo-1+ and 63.6% of non-Jo-1 ARS patients, compared with 33.3% of dcSS patients. Similarly, 72.7% of ARS patients (54.5% Jo-1+ and 90.9% non-Jo-1) and 55.6% of dcSS had severe gas exchange deficits. Supplemental oxygen use was 25.9% in ARS and 14.3% in dcSS. Despite the prevalence of ILD at 45% and 43.9% in lcSS and DM, respectively, physiologic severity was less than for ARS or dcSS. FVC was severely restricted in only 12.5% of lcSS cases and 5.6% of DM cases. Over 62% of lcSS patients had severe reduction in DLCO, but this is likely due to concomitant pulmonary hypertension. The time from symptom onset to first PFT or HRCT was the shortest with the ARS group (Figure 1). ARS patients (72.7%), particularly the non-Jo-1 ARS (100%), were more likely than other groups (34%) to be seen first in pulmonary clinic. 

Conclusion: In our cohort, ARS had the highest prevalence and severity of ILD. ARS patients, especially non-Jo-1 ARS patients, were more likely to be seen initially in pulmonary clinic and receive earlier screening for ILD. However, these patients may also have delayed diagnosis due to lack of extra-pulmonary symptoms thus presenting with more severe disease. Implementing routine screening for ARS in pulmonary clinics may identify patients earlier and change management.


Table 1


Table 2


Figure 1


Disclosure: B. Sohn, None; E. Wilfong, None; L. Crofford, None.

To cite this abstract in AMA style:

Sohn B, Wilfong E, Crofford L. Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/patients-with-anti-trna-synthetase-syndrome-are-more-likely-to-present-to-pulmonary-clinic-and-have-a-higher-prevalence-and-severity-of-lung-disease-than-patients-with-other-types-of-myositis-or-syste/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-anti-trna-synthetase-syndrome-are-more-likely-to-present-to-pulmonary-clinic-and-have-a-higher-prevalence-and-severity-of-lung-disease-than-patients-with-other-types-of-myositis-or-syste/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology